Activators & Inhibitors

CVN636, a potent and selective allosteric agonist for the mGluR7 receptor, exhibits oral activity and CNS permeability [1], with an EC50 of 7 nM for human mGluR7.

NCGC00138783 TFA acts as a selective inhibitor of the CD47/SIRPα axis, exhibiting an inhibitory concentration (IC50) of 50 μM. This compound effectively obstructs the interaction between CD47 and SIRPα [1] [2].

MitoCur-1, a curcumin analogue, inhibits the mitochondrial antioxidative enzyme thioredoxin reductase 2 (TrxR2) and possesses electrophilic characteristics with mitochondrial-targeting capabilities. This compound specifically induces reactive oxygen species (ROS) generation, demonstrating antitumor efficacy [1].

Lemzoparlimab (TJ011133; TJC4), a humanized anti-CD47 IgG4 antibody, exhibits potent antitumor activity [1].

Anti-Mouse IL-1b Antibody is an IgG inhibitor specific to mouse IL-1b, derived from an Armenian Hamster host.

Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human IgG. It functions by inhibiting B cell activation through binding to both B lymphocyte stimulator and a proliferation-inducing ligand, and is utilized in researching B-cell autoimmune diseases [1] [2].

Baminercept (BG 9924), an IgG fusion protein targeting the lymphotoxin β receptor (LTβR-Ig), has potential applications in the study of various autoimmune diseases, such as primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) [1] [2].

Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.

Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1].